---
document_datetime: 2025-12-02 05:37:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/elmiron.html
document_name: elmiron.html
version: success
processing_time: 0.1109898
conversion_datetime: 2025-12-24 18:23:19.22501
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Elmiron

[RSS](/en/individual-human-medicine.xml/65543)

##### Authorised

This medicine is authorised for use in the European Union

pentosan polysulfate sodium Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Elmiron](#news-on)
- [More information on Elmiron](#more-information-on-elmiron-463)
- [More information on Elmiron](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Elmiron. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Elmiron.

For practical information about using Elmiron, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Elmiron and what is it used for?

Elmiron is a medicine used to treat adults with bladder pain syndrome, a condition of the bladder which causes pain in the pelvic area and a frequent, urgent need to pass urine.

Elmiron is used in patients with moderate to severe pain and who have small bleeds or lesions (sores) in the bladder wall.

Elmiron contains the active substance pentosan polysulfate sodium.

## How is Elmiron used?

Elmiron is available as 100-mg capsules and can only be obtained with a prescription. The recommended dose is one capsule taken three times a day.

Patients should be assessed every six months and treatment should be stopped if no improvement is seen.

For further information, see the package leaflet.

## How does Elmiron work?

The way the active substance in Elmiron, pentosan polysulfate sodium, works is not fully understood but it passes into the urine and is thought to attach to and help repair the protective layer of mucus lining the bladder, which is deficient in patients with bladder pain syndrome. This reinforcement of the protective layer may reduce inflammation and bladder pain.

## What benefits of Elmiron have been shown in studies?

Because pentosan polysulfate sodium is a well-known substance, and its use in bladder pain syndrome is well established, the company for Elmiron presented data from the scientific literature. A review of 4 main studies from the literature showed that pentosan polysulfate sodium is effective at reducing symptoms, such as pain and the urge to pass urine frequently.

The studies involved a total of 454 patients with small bleeds and lesions in the bladder wall. Looking at the results of the 4 studies together, 1 in 3 (33%) patients taking pentosan polysulfate sodium showed an overall improvement in their condition compared with around 1 in 6 (16%) patients taking placebo (a dummy treatment).

## What are the risks associated with Elmiron?

The most common side effects with Elmiron (which may affect up to 1 in 10 people) include headache, dizziness, and effects in the digestive systems such as diarrhoea, nausea (feeling sick), abdominal (belly) pain and bleeding from the rectum. Since Elmiron may have a weak anticoagulant effect (i.e. it may stop the blood from clotting properly), it must not be used in patients who actively bleed (but this does not include women during menstrual cycle). For the full list of all side effects and restrictions with Elmiron, see the package leaflet.

## Why is Elmiron approved?

Bladder pain syndrome is a distressing condition for which no medicines were previously approved in the EU. In patients with small bleeds and lesions in the bladder wall, treatment with Elmiron led to significantly more patients having an overall improvement in symptoms.

No major safety concerns were identified, and the possible risk of bleeding can be minimised with appropriate precautions.

The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Elmiron's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Elmiron?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elmiron have been included in the summary of product characteristics and the package leaflet.

## Other information about Elmiron

The European Commission granted a marketing authorisation valid throughout the European Union for Elmiron on 2 June 2017.

For more information about treatment with Elmiron, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Elmiron : EPAR - Summary for the public

Reference Number: EMA/213902/2017

English (EN) (74.72 KB - PDF)

**First published:** 20/06/2017

**Last updated:** 20/06/2017

[View](/en/documents/overview/elmiron-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-143)

български (BG) (98.64 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/bg/documents/overview/elmiron-epar-summary-public_bg.pdf)

español (ES) (73.78 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/es/documents/overview/elmiron-epar-summary-public_es.pdf)

čeština (CS) (97.88 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/cs/documents/overview/elmiron-epar-summary-public_cs.pdf)

dansk (DA) (72.47 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/da/documents/overview/elmiron-epar-summary-public_da.pdf)

Deutsch (DE) (74.73 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/de/documents/overview/elmiron-epar-summary-public_de.pdf)

eesti keel (ET) (71.84 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/et/documents/overview/elmiron-epar-summary-public_et.pdf)

ελληνικά (EL) (99.03 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/el/documents/overview/elmiron-epar-summary-public_el.pdf)

français (FR) (74.42 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/fr/documents/overview/elmiron-epar-summary-public_fr.pdf)

hrvatski (HR) (92.29 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/hr/documents/overview/elmiron-epar-summary-public_hr.pdf)

italiano (IT) (72.31 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/it/documents/overview/elmiron-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.95 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/lv/documents/overview/elmiron-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (94.94 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/lt/documents/overview/elmiron-epar-summary-public_lt.pdf)

magyar (HU) (91.36 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/hu/documents/overview/elmiron-epar-summary-public_hu.pdf)

Malti (MT) (120.26 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/mt/documents/overview/elmiron-epar-summary-public_mt.pdf)

Nederlands (NL) (73.89 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/nl/documents/overview/elmiron-epar-summary-public_nl.pdf)

polski (PL) (98.35 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/pl/documents/overview/elmiron-epar-summary-public_pl.pdf)

português (PT) (73.87 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/pt/documents/overview/elmiron-epar-summary-public_pt.pdf)

română (RO) (94.02 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/ro/documents/overview/elmiron-epar-summary-public_ro.pdf)

slovenčina (SK) (96.08 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/sk/documents/overview/elmiron-epar-summary-public_sk.pdf)

slovenščina (SL) (90.66 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/sl/documents/overview/elmiron-epar-summary-public_sl.pdf)

Suomi (FI) (72.08 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/fi/documents/overview/elmiron-epar-summary-public_fi.pdf)

svenska (SV) (72.51 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

20/06/2017

[View](/sv/documents/overview/elmiron-epar-summary-public_sv.pdf)

## Product information

Elmiron : EPAR - Product Information

English (EN) (197.67 KB - PDF)

**First published:** 20/06/2017

**Last updated:** 15/07/2022

[View](/en/documents/product-information/elmiron-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-165)

български (BG) (304.39 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/bg/documents/product-information/elmiron-epar-product-information_bg.pdf)

español (ES) (200.69 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/es/documents/product-information/elmiron-epar-product-information_es.pdf)

čeština (CS) (277.78 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/cs/documents/product-information/elmiron-epar-product-information_cs.pdf)

dansk (DA) (203.76 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/da/documents/product-information/elmiron-epar-product-information_da.pdf)

Deutsch (DE) (209.15 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/de/documents/product-information/elmiron-epar-product-information_de.pdf)

eesti keel (ET) (177.87 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/et/documents/product-information/elmiron-epar-product-information_et.pdf)

ελληνικά (EL) (299.63 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/el/documents/product-information/elmiron-epar-product-information_el.pdf)

français (FR) (209.91 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/fr/documents/product-information/elmiron-epar-product-information_fr.pdf)

hrvatski (HR) (264.2 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/hr/documents/product-information/elmiron-epar-product-information_hr.pdf)

íslenska (IS) (178.37 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/is/documents/product-information/elmiron-epar-product-information_is.pdf)

italiano (IT) (203.28 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/it/documents/product-information/elmiron-epar-product-information_it.pdf)

latviešu valoda (LV) (291.6 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/lv/documents/product-information/elmiron-epar-product-information_lv.pdf)

lietuvių kalba (LT) (284.67 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/lt/documents/product-information/elmiron-epar-product-information_lt.pdf)

magyar (HU) (291.02 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/hu/documents/product-information/elmiron-epar-product-information_hu.pdf)

Malti (MT) (293.41 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/mt/documents/product-information/elmiron-epar-product-information_mt.pdf)

Nederlands (NL) (200.73 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/nl/documents/product-information/elmiron-epar-product-information_nl.pdf)

norsk (NO) (204.04 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/no/documents/product-information/elmiron-epar-product-information_no.pdf)

polski (PL) (278.52 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/pl/documents/product-information/elmiron-epar-product-information_pl.pdf)

português (PT) (204.03 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/pt/documents/product-information/elmiron-epar-product-information_pt.pdf)

română (RO) (283.29 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/ro/documents/product-information/elmiron-epar-product-information_ro.pdf)

slovenčina (SK) (262.56 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/sk/documents/product-information/elmiron-epar-product-information_sk.pdf)

slovenščina (SL) (276.88 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/sl/documents/product-information/elmiron-epar-product-information_sl.pdf)

Suomi (FI) (200.01 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/fi/documents/product-information/elmiron-epar-product-information_fi.pdf)

svenska (SV) (198.76 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

15/07/2022

[View](/sv/documents/product-information/elmiron-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0027 15/07/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Elmiron : EPAR - All Authorised presentations

English (EN) (47.74 KB - PDF)

**First published:** 20/06/2017

**Last updated:** 03/02/2022

[View](/en/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-516)

български (BG) (37.05 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/bg/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.51 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/es/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.76 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/cs/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.31 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/da/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.55 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/de/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.48 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/et/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.97 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/el/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_el.pdf)

français (FR) (15.34 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/fr/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.88 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/hr/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.21 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/is/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.43 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/it/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.53 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/lv/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.9 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/lt/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.8 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/hu/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.92 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/mt/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.28 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/nl/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.04 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/no/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.32 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/pl/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.38 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/pt/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.68 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/ro/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.89 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/sk/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.76 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/sl/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.31 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/fi/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.29 KB - PDF)

**First published:**

20/06/2017

**Last updated:**

03/02/2022

[View](/sv/documents/all-authorised-presentations/elmiron-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Elmiron Active substance pentosan polysulfate sodium International non-proprietary name (INN) or common name pentosan polysulfate sodium Therapeutic area (MeSH) Cystitis, Interstitial Anatomical therapeutic chemical (ATC) code G04BX15

### Pharmacotherapeutic group

Urologicals

### Therapeutic indication

Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.

## Authorisation details

EMA product number EMEA/H/C/004246 Marketing authorisation holder

bene-Arzneimittel GmbH

Herterichstrasse 1-3

Marketing authorisation issued 02/06/2017 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Elmiron : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (163.38 KB - PDF)

**First published:** 27/09/2017

**Last updated:** 15/07/2022

[View](/en/documents/procedural-steps-after/elmiron-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Elmiron-H-C-PSUSA-00010614-201906 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/24641/2020

English (EN) (124.82 KB - PDF)

**First published:** 17/04/2020

[View](/en/documents/scientific-conclusion/elmiron-h-c-psusa-00010614-201906-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Elmiron-H-C-PSUSA-00010614-201812 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/342325/2019

English (EN) (71.86 KB - PDF)

**First published:** 04/09/2019

[View](/en/documents/scientific-conclusion/elmiron-h-c-psusa-00010614-201812-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Elmiron : EPAR - Public assessment report

Adopted

Reference Number: EMA/287422/2017

English (EN) (2.79 MB - PDF)

**First published:** 20/06/2017

**Last updated:** 20/06/2017

[View](/en/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Elmiron

Adopted

Reference Number: EMA/158291/2017

English (EN) (68.94 KB - PDF)

**First published:** 24/03/2017

**Last updated:** 24/03/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-elmiron_en.pdf)

#### News on Elmiron

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-march-2017) 24/03/2017

#### More information on Elmiron

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu3141411) on 15 January 2015. Elmiron was withdrawn from the Community register of orphan medicinal products in 11 April 2017 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Elmiron

- [ELMIRON: Observational Study for the Characterisation of Treatment Practice, Patients, and Symptom Load of Oral Pentosane Polysulfate Sodium for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome - post-authorisation study](https://catalogues.ema.europa.eu/study/44360)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/07/2022

## Share this page

[Back to top](#main-content)